Porownywarka

Copper Peptide AHK-Cu vs Argireline side-by-side

Zestaw do czterech peptydów według statusu dowodów, mechanizmów, dawkowania z badań, skutków ubocznych i referencji.

Wybrane (2/4)

Copper Peptide AHK-CuArgireline

Udostępnij porównanie peptydów

Wlasciwosc	Copper Peptide AHK-Cu	Argireline
Kategoria	Skóra i włosy	Skóra i włosy
Znany tez jako	Tripeptide-3, Ala-His-Lys Copper	Acetyl Hexapeptide-3, Acetyl Hexapeptide-8
Zatwierdzony przez FDA	Nie	Nie
Status kliniczny	Cosmetic use - Hair care products Pre Przedkliniczne I Faza I II Faza II III Faza III IV Faza IV FDA Zatwierdzone przez FDA	Cosmetic use - widely available Pre Przedkliniczne I Faza I II Faza II III Faza III IV Faza IV FDA Zatwierdzone przez FDA
Czego oczekiwac	Hair growth, scalp health, hair thickness	Wrinkle reduction, forehead lines, eye area anti-aging
Jak dziala	AHK-Cu is described as a copper-bound alanine-histidine-lysine tripeptide. In the supplied material, its proposed hair-related mechanism is centered on copper signaling in follicle-associated biology, especially dermal papilla cells. Reported cell and isolated-follicle findings include increased dermal papilla cell proliferation, reduced apoptosis markers, and a shift in survival-related proteins with higher Bcl-2 and lower Bax. The source explicitly limits these mechanistic observations to cells and isolated follicles rather than proven human scalp outcomes.	Argireline is described as an acetyl hexapeptide-8 fragment connected to SNAP-25, a protein involved in the SNARE machinery for acetylcholine release. The source reports that early laboratory work found neurotransmitter-release inhibition in cell systems. A key limitation is topical delivery: the supplied review summary notes disagreement about skin penetration and states that in vivo demonstration of the marketed muscle-inhibition mechanism was not shown.
Typowe dawkowanie	Limited community data available · See research protocols	Limited community data available · See research protocols
Dawkowanie z badań	Topical solutions and serums · 3-6 months for visible results · Topical (scalp serums, solutions)	5-10% concentration in formulations · Ongoing use for maintained effects · Topical (serums, creams)
Typowy czas trwania	3-6 months for visible results	Ongoing use for maintained effects
Podanie	Topical (scalp serums, solutions)	Topical (serums, creams)
Timing	Morning or as directed With or without food	Morning and evening (topical) With or without food
Poziom dowodów	Badawcze	Badawcze
Mozliwe skutki uboczne	Generally well-tolerated Skin irritation Allergic reactions (Rare) +2 więcej Risk of copper toxicity if combined with copper sources (Source flags this as a caution when other copper sources are also used.) Contraindicated with Wilson's disease (Source lists Wilson's disease as a contraindication.)	Generally very safe (Reported in source as a general safety characterization; not an FDA safety determination.) Mild skin irritation (Rare in the supplied source.) Redness or tingling (Rare in the supplied source.) +1 więcej Fewer side effects than botulinum toxin (Comparative statement from source; does not establish equivalence or treatment substitution.)
Podsumowanie researchu	The main research signal supplied is a 2007 Archives of Pharmacal Research study by Pyo and colleagues. The source states that AHK-Cu was tested outside the body using human hair follicles and dermal papilla cells. At low concentrations, it reportedly increased isolated follicle length and dermal papilla cell proliferation while lowering apoptosis-related markers. The source also notes a narrow dose-response pattern in which higher concentrations no longer showed the same activity. The important limitation is that the source does not identify randomized controlled human trials showing that topical AHK-Cu regrows or thickens scalp hair in people.	The source summary cites a 2002 Blanes-Mira study using a 10% peptide oil-in-water emulsion and reporting a 30% wrinkle-depth reduction, alongside cell-assay support for SNARE interference. It also describes a small double-blind split-face study in 19 women where four weeks of Argireline serum did not significantly outperform placebo by VISIA imaging and was not considered a botulinum toxin substitute. A 2025 review is reported to have found inconsistent penetration estimates, about 30% stratum-corneum passage in one study versus about 0.2% in another, and no in vivo proof of the proposed muscle-inhibition mechanism. Overall, the supplied evidence frames Argireline as a plausible cosmetic peptide with limited and mixed human data, while noting no serious adverse effects reported.
Referencje	PubMed Springer +1 więcej Semantic Scholar	PubMed Wiley Online Library +3 więcej PubMed Central PubMed Central WikipediaAcetyl hexapeptide-8
Pełny profil	Zobacz szczegóły	Zobacz szczegóły

Zapisz to porównanie

Trzymaj ten zestaw researchowy pod reka na darmowym koncie PeptiGuide.

Zapisz porównanie - darmowe konto

Trackuj swoja ścieżkę peptydówa

Zamien research w prywatny log protokołu, gdy będziesz gotowy.

Trackuj ścieżkę peptydówa

Wyłącznie edukacyjnie. Te informacje są agregowane z publicznych badań i raportów społeczności. To nie jest poradą medyczną, a informacje o dawkowaniu są opisowe, nie rekomendacyjne. Zawsze konsultuj się z wykwalifikowanym specjalistą ochrony zdrowia.

Wlasciwosc

Copper Peptide AHK-Cu

Argireline

Kategoria

Skóra i włosy

Znany tez jako

Tripeptide-3, Ala-His-Lys Copper

Acetyl Hexapeptide-3, Acetyl Hexapeptide-8

Zatwierdzony przez FDA

Nie

Status kliniczny

Cosmetic use - Hair care products

Pre
Przedkliniczne
I
Faza I
II
Faza II
III
Faza III
IV
Faza IV
FDA
Zatwierdzone przez FDA

Cosmetic use - widely available

Pre
Przedkliniczne
I
Faza I
II
Faza II
III
Faza III
IV
Faza IV
FDA
Zatwierdzone przez FDA

Czego oczekiwac

Hair growth, scalp health, hair thickness

Wrinkle reduction, forehead lines, eye area anti-aging

Jak dziala

AHK-Cu is described as a copper-bound alanine-histidine-lysine tripeptide. In the supplied material, its proposed hair-related mechanism is centered on copper signaling in follicle-associated biology, especially dermal papilla cells. Reported cell and isolated-follicle findings include increased dermal papilla cell proliferation, reduced apoptosis markers, and a shift in survival-related proteins with higher Bcl-2 and lower Bax. The source explicitly limits these mechanistic observations to cells and isolated follicles rather than proven human scalp outcomes.

Argireline is described as an acetyl hexapeptide-8 fragment connected to SNAP-25, a protein involved in the SNARE machinery for acetylcholine release. The source reports that early laboratory work found neurotransmitter-release inhibition in cell systems. A key limitation is topical delivery: the supplied review summary notes disagreement about skin penetration and states that in vivo demonstration of the marketed muscle-inhibition mechanism was not shown.

Typowe dawkowanie

Limited community data available · See research protocols

Dawkowanie z badań

Topical solutions and serums · 3-6 months for visible results · Topical (scalp serums, solutions)

5-10% concentration in formulations · Ongoing use for maintained effects · Topical (serums, creams)

Typowy czas trwania

3-6 months for visible results

Ongoing use for maintained effects

Podanie

Topical (scalp serums, solutions)

Topical (serums, creams)

Timing

Morning or as directed

With or without food

Morning and evening (topical)

With or without food

Poziom dowodów

Badawcze

Mozliwe skutki uboczne

Generally well-tolerated
Skin irritation
Allergic reactions (Rare)

+2 więcej

Risk of copper toxicity if combined with copper sources (Source flags this as a caution when other copper sources are also used.)
Contraindicated with Wilson's disease (Source lists Wilson's disease as a contraindication.)

Generally very safe (Reported in source as a general safety characterization; not an FDA safety determination.)
Mild skin irritation (Rare in the supplied source.)
Redness or tingling (Rare in the supplied source.)

+1 więcej

Fewer side effects than botulinum toxin (Comparative statement from source; does not establish equivalence or treatment substitution.)

Podsumowanie researchu

The main research signal supplied is a 2007 Archives of Pharmacal Research study by Pyo and colleagues. The source states that AHK-Cu was tested outside the body using human hair follicles and dermal papilla cells. At low concentrations, it reportedly increased isolated follicle length and dermal papilla cell proliferation while lowering apoptosis-related markers. The source also notes a narrow dose-response pattern in which higher concentrations no longer showed the same activity. The important limitation is that the source does not identify randomized controlled human trials showing that topical AHK-Cu regrows or thickens scalp hair in people.

The source summary cites a 2002 Blanes-Mira study using a 10% peptide oil-in-water emulsion and reporting a 30% wrinkle-depth reduction, alongside cell-assay support for SNARE interference. It also describes a small double-blind split-face study in 19 women where four weeks of Argireline serum did not significantly outperform placebo by VISIA imaging and was not considered a botulinum toxin substitute. A 2025 review is reported to have found inconsistent penetration estimates, about 30% stratum-corneum passage in one study versus about 0.2% in another, and no in vivo proof of the proposed muscle-inhibition mechanism. Overall, the supplied evidence frames Argireline as a plausible cosmetic peptide with limited and mixed human data, while noting no serious adverse effects reported.

Referencje

PubMed Springer

+1 więcej

Semantic Scholar

PubMed Wiley Online Library

+3 więcej

PubMed Central PubMed Central WikipediaAcetyl hexapeptide-8

Pełny profil

Zobacz szczegóły